Your browser doesn't support javascript.
loading
2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma.
Bedke, Jens; Albiges, Laurence; Capitanio, Umberto; Giles, Rachel H; Hora, Milan; Lam, Thomas B; Ljungberg, Börje; Marconi, Lorenzo; Klatte, Tobias; Volpe, Alessandro; Abu-Ghanem, Yasmin; Dabestani, Saeed; Fernández-Pello, Sergio; Hofmann, Fabian; Kuusk, Teele; Tahbaz, Rana; Powles, Thomas; Bex, Axel.
Afiliación
  • Bedke J; Department of Urology, University Hospital Tuebingen, Tuebingen, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Albiges L; Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Capitanio U; Department of Urology, San Raffaele Scientific Institute, Milan, Italy; Division of Experimental Oncology/Unit of Urology, URI, IRCCS San Raffaele Hospital, Milan, Italy.
  • Giles RH; International Kidney Cancer Coalition (IKCC), Duivendrecht, The Netherlands.
  • Hora M; Department of Urology, University Hospital Pilsen and Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic.
  • Lam TB; Academic Urology Unit, University of Aberdeen, Aberdeen, UK; Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK.
  • Ljungberg B; Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.
  • Marconi L; Department of Urology, Coimbra University Hospital, Coimbra, Portugal.
  • Klatte T; Department of Urology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Volpe A; Department of Urology, University of Eastern Piedmont, Maggiore della Carità Hospital, Novara, Italy.
  • Abu-Ghanem Y; Department of Urology, Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel.
  • Dabestani S; Department of Translational Medicine, Division of Urological Cancers, Lund University, Malmö, Sweden.
  • Fernández-Pello S; Department of Urology, Cabueñes University Hospital, Gijón, Spain.
  • Hofmann F; Department of Urology, Sunderby Sjukhus, Umeå University, Luleå, Sweden.
  • Kuusk T; Department of Urology, Darent Valley Hospital, Dartford, UK; Gravesham NHS Trust, Dartford, UK.
  • Tahbaz R; Department of Urology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Powles T; The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK.
  • Bex A; The Royal Free London NHS Foundation Trust, London, UK; UCL Division of Surgery and Interventional Science, London, UK; Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Electronic address: a.bex@nki.nl.
Eur Urol ; 81(2): 134-137, 2022 02.
Article en En | MEDLINE | ID: mdl-34920897
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Urología / Carcinoma de Células Renales / Neoplasias Renales Tipo de estudio: Guideline / Qualitative_research / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: Eur Urol Año: 2022 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Urología / Carcinoma de Células Renales / Neoplasias Renales Tipo de estudio: Guideline / Qualitative_research / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: Eur Urol Año: 2022 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza